Immuneering Reconciled Depreciation from 2010 to 2024

IMRX Stock  USD 2.08  0.02  0.95%   
Immuneering Corp Reconciled Depreciation yearly trend continues to be fairly stable with very little volatility. Reconciled Depreciation is likely to outpace its year average in 2024. During the period from 2010 to 2024, Immuneering Corp Reconciled Depreciation regression line of annual values had r-squared of  0.55 and arithmetic mean of  198,424. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2010-12-31
Previous Quarter
858.7 K
Current Value
901.7 K
Quarterly Volatility
341.2 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immuneering Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immuneering Corp's main balance sheet or income statement drivers, such as Net Interest Income of 3.5 M, Interest Income of 3.5 M or Depreciation And Amortization of 369.7 K, as well as many indicators such as Price To Sales Ratio of 207, Dividend Yield of 0.0 or PTB Ratio of 2.42. Immuneering financial statements analysis is a perfect complement when working with Immuneering Corp Valuation or Volatility modules.
  
Check out the analysis of Immuneering Corp Correlation against competitors.
For more information on how to buy Immuneering Stock please use our How to Invest in Immuneering Corp guide.

Latest Immuneering Corp's Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of Immuneering Corp over the last few years. It is Immuneering Corp's Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immuneering Corp's overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

Immuneering Reconciled Depreciation Regression Statistics

Arithmetic Mean198,424
Geometric Mean49,834
Coefficient Of Variation171.94
Mean Deviation261,589
Median18,079
Standard Deviation341,173
Sample Variance116.4B
Range883.6K
R-Value0.74
Mean Square Error56.2B
R-Squared0.55
Significance0
Slope56,679
Total Sum of Squares1.6T

Immuneering Reconciled Depreciation History

2024901.7 K
2023858.7 K
2022796.8 K
2021159.1 K
202079.3 K

About Immuneering Corp Financial Statements

Immuneering Corp investors use historical fundamental indicators, such as Immuneering Corp's Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immuneering Corp. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Reconciled Depreciation858.7 K901.7 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immuneering Stock Analysis

When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.